Yumastem and 3 Other Companies Join Hands to Activate Autologous Adipose Stem Cells

[Asia Economy Reporter Kim Heung-soon] Domestic stem cell research and development (R&D) companies, stem cell medical experts, and medical consulting firms are collaborating to establish a 'Customized Autologous Adipose Stem Cell Global Complex Platform.'

Stem cell R&D company Hurim BioCell, cell banking sales specialist Hurim Healthcare, YumaStem Medical Group operating an autologous adipose stem cell clinic network, and medical consulting firm TNM Holdings announced on the 29th that they have signed a business agreement to build a customized autologous adipose stem cell complex platform.

These companies plan to collaborate domestically and internationally for the development of autologous adipose stem cell therapeutics, stem cell raw materials for cosmeceuticals, cell banking business for storing stem cells and immune cells, and autologous adipose stem cell specialized clinic network business.

Since its founding in 2005, Hurim BioCell has focused on developing stem cell-based treatments for vitiligo and liver diseases through national projects and independent clinical research. It holds 27 domestic patents and 6 overseas patents. Since 2011, it began umbilical cord blood banking and expanded its operations to immune and stem cell cell banking sales from 2018.

YumaStem Medical Group has demonstrated expertise in beauty anti-aging, immune skin diseases, joint regeneration, pain, and physical function improvement due to aging. It plans to develop clinic network business with TNM Holdings, which manages domestic and international clinic networks. It will also serve as a clinical academic research institution for Hurim BioCell.

First, a comprehensive clinic center of approximately 300 pyeong will open in January 2021 in the SK Knowledge Industry Complex in Anyang, Gyeonggi Province. This center will operate outpatient internal medicine, surgery, and pain and rehabilitation specialty centers for local residents. Additionally, Hurim BioCell will establish a stem cell medical clinical research institute within the hospital.

A YumaStem official said, "We hope that the joint stem cell business of the four companies will be a solution for maintaining public health and future disease treatment."

This content was produced with the assistance of AI translation services.